Background: We recently reported that protection against coronary artery disease (CAD) mortality is the major contributor to longer life associated with FOXO3 genotype. The present study examined this relation in more detail. Methods: We performed a 15-year observational study of 3,584 older American men of Japanese ancestry from the Kuakini Honolulu Heart Program cohort and 1,595 White and 1,067 Black elderly individuals from the Health Aging and Body Composition study.
Genetic variants in the forkhead box-O3 (FoxO3) gene (FOXO3) are strongly associated with human longevity (1) . The association has been consistently replicated in multiple long-lived population subgroups worldwide (2, 3) . We recently reported that the major reason is protection against death from coronary artery disease (CAD) (4) . That study involved American men of Japanese ancestry from the Kuakini Honolulu Heart Program (HHP) cohort, and replication in White and Black elderly individuals from the Health Aging and Body Composition (ABC) cohort. Over a 17-year follow-up, we found carriers of the minor (G) allele of the most prominent longevity-associated FOXO3 single nucleotide polymorphism (SNP), rs2802292, had a combined (Japanese, White, and Black populations) risk reduction of 10% for total (all cause) mortality.
In the present study, we used data from these cohorts to (i) compare the contribution of the longevity-associated (G) allele of rs2802292 to common known risk factors for CAD mortality in a multivariable model, (ii) measure the potential population impact of FOXO3 genotype in a population-attributable risk (PAR) model, and (iii) assess potential mechanisms.
Methods
Study participants, demographic characteristics, DNA extraction, and genotyping were as described previously (4) . Inflammatory markers (tumor necrosis factor [TNF]-α) and C-reactive protein (CRP) were measured in Kuakini HHP study participants at HHP Examination 2 (CRP: 1967 (CRP: -1970 ) and HHP Exam 4 (TNF-α: 1991-1993), when participants were aged 56.4 years (range: 48-70 years) and 77.8 years (range: 71-93 years), respectively. Plasma TNF-α was measured using Luminex 200 and the HSTCMAG-28SK kit (EMD Millipore, Billerica, MA), and CRP was measured by an enzymelinked immunosorbent assay as described previously (5) . Coronary calcium scores were measured at HHP Examination 9 (2003 Examination 9 ( -2005 by the Agatston method. The differences in TNF-α and CRP levels between genotypes were tested by t test using the Satterthwaite method. Fifteen-year survival curves, standardized at the age of 73 years (mean age at baseline), for carriers versus noncarriers of the G allele of rs2802292 were generated by Cox regression with baseline statement using the SAS PHREG procedure (SAS Institute, Cary, NC). PAR was calculated by indirect standardization, stratified by age group 71-74, 75-79, 80-84, and 85+ years (6) . Statistical analyses were performed using SAS version 9.3 (SAS Institute). A metaanalysis to test the differences in log-transformed TNF-α and CRP by G-allele carrier status was conducted using the program Stata version 12.1 (Stata Corp, College Station, TX).
Results
Characteristics of the participants and percentage of G-allele carriers in each racial group are shown in Supplementary Table 1 . Japanese, White, and Black FOXO3 G-allele carriers exhibited lower CAD mortality during follow-up (Figure 1 ). Risk factors for CAD mortality and hazard ratio (HR) in each racial group are shown in Table 1 . Multivariable Cox regression models adjusting for these common risk factors for carriers and noncarriers of the G allele found that over this 15-year period, the G allele conferred a significant protective effect against CAD mortality in Japanese (HR = 0.68; 95% CI 0.55-0.83; p < .001) and Whites (HR = 0.76; 95% CI 0.58-1.00; p = .049). Although HR for CAD mortality in G-allele carriers was 33% lower than noncarriers in Blacks, this did not reach statistical significance after adjustment for major CAD risk factors (HR = 0.67; 95% CI 0.39-1.16; p = .14), but was marginally significant when adjusted for age and gender (HR = 0.59; 95% CI 0.34-1.01; p = .054). CAD prevalence was lower in Japanese and White, but not in Black, G-allele carriers (Supplementary Table 2) .
PAR was calculated, and adjusted for 5-year age group (71-74, 75-79, 80-84, and 85+ years), from the number of CAD deaths of those exposed and unexposed to various risk factors at the baseline exam for each population, including the FOXO3 nonprotective ("risk") genotype, TT (Table 2) (6). PAR for the TT genotype for Japanese, White, and Black participants was 15%, 9%, and 3%, respectively. In Japanese, PAR for TT genotype was comparable with PAR for hypertension (15%). In contrast, in Whites and Blacks, PAR for hypertension was higher than PAR for TT genotype (Whites 29% vs. 9%, respectively; Blacks 26% vs. 3%, respectively). In Whites, PAR for having been a smoker was higher than TT genotype (12% vs. 9%, respectively). The only other significant PAR was for elevated fasting plasma cholesterol in Japanese (2%).
Inflammatory marker plasma TNF-α was significantly lower in Japanese G-allele carriers (p = .0086), but in Whites and Blacks, the lower TNF-α level in G-allele carriers did not reach statistical significance (Table 3) . Data for each were skewed, but after logarithmic transformation approximated a normal distribution. A fixed-effects meta-analysis of log-transformed data for each racial group was statistically significant (p = .018). No significant heterogeneity was detected for the three populations (p = .97), demonstrating that the populations were appropriate for meta-analysis. Because n value for TNF-α data was low, a significant result after adjusting for TNF-α as a risk factor in Cox regression analysis could not be obtained.
Fixed-effects meta-analysis of log-transformed CRP data for each racial group indicated a suggestive association with G-allele carriage (p = .059) (Supplementary Table 3 ).
Coronary calcium score was lower in Japanese G-allele carriers compared with noncarriers (Supplementary Table 4) , suggestive of a possible protective effect against the atherosclerotic process in the coronary vasculature.
G-allele carriers were at lower risk of CAD mortality whether they had diabetes or not (Supplementary Table 5a ). Diabetic G-allele carriers were at equivalent risk of CAD mortality as nondiabetic participants with the TT genotype (Supplementary Table 5b ). Supplementary Table 5c shows that diabetics with the TT genotype were at higher risk of CAD mortality than diabetic G-allele carriers, followed by nondiabetic TT, then nondiabetic GT/GG genotype.
Discussion
Clinical genomics is a rapidly advancing field that holds promise for improving medical decision-making and clinical outcomes (7) . Yet in CAD, few genes have been identified with alleles that have Notes: ABC = Aging and Body Composition; CAD = coronary artery disease; CI = confidence interval; HHP = Honolulu Heart Program; HR = hazard ratio. The protective effect of G-allele carriage (GG/GT genotype) was little changed in multivariate models adjusted for major risk factors, suggesting a mechanism independent of common cardiovascular disease risk factors in Japanese and Whites. In contrast, in Blacks, the risk factor model was rendered nonsignificant, suggesting that there are one or more risk factors in the biological pathway in Blacks. Notes: ABC= Aging and Body Composition; CAD = coronary artery disease. Population-attributable risk (PAR) was adjusted for 5-year age group, using the indirect method, from the number of CAD deaths of those exposed and unexposed to various risk factors at Examination 4 (1991-1993), including the FOXO3 TT nonprotective ("risk") genotype. PAR for FOXO3 TT genotype was strong in Japanese relative to the other risk factors shown. In Whites, PAR for TT genotype was weaker than hypertension or ever having been a smoker. In Blacks, it was not significant. -0.20 to -0.019 100.0 CI = confidence interval; SMD = standardized mean difference (= difference in mean outcome between groups divided by standard deviation of outcome among participants); TNF-α = tumor necrosis factor-α.
Test of SMD = 0: z = 2.37; p = .018. a For Japanese, a random sample of 150 was tested, yielding valid data for 123 samples and genotype frequencies similar to the main cohort. major clinical implications. This is because risk alleles with a strong effect size tend to be rare and PAR depends on both effect size and the prevalence of the risk factor in the population (8) . Long-lived persons tend to delay or avoid age-related diseases, such as CAD. A likely reason is a substantial genetic influence (9) . Thus long-lived populations may be fruitful for discovering genes with major clinical effects on CAD. In an extension of our recent finding that the FOXO3 G allele of rs2802292 appears to exert its effect on longevity principally by protecting against CAD (4), we now demonstrate that this genotype is not only important for longevity but exhibits a large PAR for CAD mortality in older Americans of Japanese, White, and Black heritage. This has potentially important clinical implications for CAD because most CAD deaths occur at older ages.
Our study found that the magnitude of risk for CAD death associated with the nonprotective FOXO3 genotype (TT) was equivalent to or larger than several, but not all, major CAD risk factors in the elderly adults. Because rs2802292 resides in an intron and the SNP sequence does not span any known transcription factor-binding sites, it may be that the protective effect of the G allele in the elderly adults involves another polymorphism, in linkage disequilibrium with rs2802292, that exerts a differential effect on FOXO3 expression. Interestingly, CardioGRAM, a large genome-wide association study (GWAS) of middle-aged men and women, found an association of FOXO3 SNPs with CAD prevalence, although the findings did not attain GWAS significance (2) . The protective effect we observed may apply more strongly to CAD mortality than CAD prevalence or may be more applicable to older persons.
In Japanese and Whites, but not in Blacks, the relative risk of CAD death we observed was notably independent of common risk factors in a multivariate risk factor model that included major CAD risk factors. In Blacks, our analyses suggest that one or more risk factors, such as fasting blood glucose, fasting total cholesterol, body mass index, hypertension, or history of smoking, are mediating factors in the FoxO3 biological pathway(s) linked to CAD mortality. In offspring of HHP participants, we have previously observed a weak association of FOXO3 SNPs with blood pressure and hypertension in women, but not in men (10) .
Our findings may have interesting clinical ramifications. For example, in the current study diabetic G-allele carriers were at no higher risk for CAD mortality than nondiabetic participants with the common (TT) genotype. Diabetes is such a strong risk factor for CAD that it is considered a "CAD equivalent" in clinical medicine (11) , especially when present for greater than 10 years (12) . Physicians often consider diabetics to have CAD until proven otherwise and to be at high risk for CAD mortality, so that these patients commonly undergo additional testing and tighter surveillance (11, 12) . However, without higher CAD risk than nondiabetics, elderly diabetic G-allele carriers might merit a less stringent clinical approach. This merits further study. Differences in our findings between each racial group suggest that race should also be taken into account.
The biological mechanism for the protective effect of the FOXO3 G allele of rs2802292 against CAD mortality in the elderly adults is unclear. Plasma TNF-α was significantly lower in Japanese, but was nonsignificantly lower in Whites and Blacks. However, a power analysis suggested that a larger sample size of 3,000 would be needed to ensure 80% power to detect an association of FOXO3 genotype and TNF-α in Whites and Blacks. Thus the current analysis of the latter two populations may be underpowered. Experiments in rodent models indicate that FoxO3 has numerous beneficial effects on a range of biological processes, including ones likely to be cardioprotective (see review (3)). FoxO3 also lowers blood inflammatory cytokine levels (13) . Because we found lower plasma TNF-α in G-allele carriers, inflammation would be expected to be lower in these individuals. As further support, the minor allele of a SNP in linkage disequilibrium with rs2802292 is associated with lower TNF-α and a milder clinical course of the inflammatory conditions Crohn's disease and rheumatoid arthritis (14) . Less inflammation would reduce risk for plaque formation and atherosclerosis, as seen in an atherosclerosis-prone FoxO-deficient mouse strain (15) . FoxO3 can, moreover, inhibit vascular smooth muscle cell proliferation and neointimal hyperplasia (16) , increase autophagy, decrease proliferation and cardiomyocyte cell size (17) (18) (19) (20) , and decrease oxidative stress in cardiac fibroblasts (21) . Vascular aging is in part an inflammatory process (22) . Loss of microvascular density and plasticity, together with cytokine-mediated adult stem cell dysfunction in vascular niches, are also linked to aging of the vasculature (23, 24) . Another mechanism might involve enhanced plaque stability and slower plaque progression, as seen after silencing of TNF-α converting enzyme in a rabbit model of atherosclerosis (25) .
Our findings for the cardioprotective effects of the G allele of FOXO3 rs2802292 against CAD mortality share some commonality with recent findings for the LDL receptor binding protein proprotein convertase subtilisin/kexin type 9 gene (PCSK9), for which a particular genotype exhibits protection against CHD mortality (26) . For example, inhibitors of PCSK9 were developed after studying persons who had uncommon heterozygous loss-of-function variants and very low LDL cholesterol levels. Drugs that inhibit this pathway reduce CAD mortality. Perhaps compounds that alter the FoxO3 pathway may yield similar benefits. Our novel findings prompt consideration of FOXO3 and its encoded protein, FoxO3, as potential targets for therapeutic intervention in elderly adults, as well as a need for further studies of their public health significance.
Limitations in the present study include genotyping of only one SNP, although it should be noted that all longevity-associated SNPs in FOXO3 are in strong linkage disequilibrium, meaning data for one SNP should represent data for any of the others. Future studies should test additional SNPs and haplotypes of these for association with CAD mortality. It will also be important to test the causative SNP(s), which are as yet unknown. Another limitation was the size of each population group, especially Blacks, for which n value was less than a third that of Japanese participants. Future studies should involve larger sample sizes.
In conclusion, the present study extends our finding of an association of the G allele of FOXO3 SNP rs2802292 with increased longevity by protecting against CAD mortality by highlighting its relative importance compared with well-established risk factors. It also suggests that FoxO3 may be a potential target for intervention in protection against death from CAD.
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